Replies to post #215471 on Biotech Values

[DewDiligence]

The clinicaltrials.gov listings for SAKURA-1/2 have always said completion was expected in Dec 2017, so I don't see any reason to question the integrity of RVNC's behavior.

[Bickema]

Mark Foley, RVNC Director, bought over $500k worth of stock on 11/07/17 at the open market, so we can assume they didn't have any results then or he would be violating SEC regulations.

https://www.sec.gov/Archives/edgar/data/1479290/000120919117060104/xslF345X03/doc4.xml

also from Q3 ER CC

Tyler, good afternoon. Look, we can't comment on the – on an ongoing trial. What we have reported is we completed enrollment in March of this year and that we were following patients to 36 weeks, nine months or to their return back to their starting baseline severity. So what we do know that it will be reported this quarter, but beyond the mechanisms of locking or unlocking a trial, we're not going to comment on that at this time.